In the rapidly evolving landscape, ICON’s recently published biotech sector survey provides a roadmap through the intricacies of investment confidence, funding dynam...

How risk assessments can improve E&L strategies Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) ar...

In the complex landscape of global regulations, particularly within healthcare and pharmaceutical sectors, a robust compliance strategy is essential for maintaining ...

Companies are overcoming challenges to develop, launch, and educate on new rare disease medicines faster. Rare diseases are no longer rare. Every year, people’s l...

In the dynamic world of biomanufacturing, the quest for improved efficiency and productivity continues to shape industry advancements. Among these innovations, the e...

The development of generic versions of peptides such as Semaglutide, the drug substance inside Novo Nordisk’s blockbuster drugs like Ozempic®, Rybelsus® or Wegovy®, ...

Overcoming the Challenges Facing Editors and Publishers Western blots are frequently included in scientific papers to report results when analysing proteins in a ...